IMPLEMENTING CENTRAL COMPOSITE DESIGN FOR THE DEVELOPMENT OF TACROLIMUS FILM FOR SUBLINGUAL ADMINISTRATION

JISHA MOHANAN; GOPINATH SUBRAMANIYAN; ARUL KUTTALINGAM; DAMODHARAN NARAYANASAMY

doi:10.22159/ijap.2023v15i3.47265

Authors

JISHA MOHANAN College of Pharmaceutical Sciences, Government Medical College, Thiruvananthapuram 695011, Kerala, India https://orcid.org/0000-0003-1421-6147
GOPINATH SUBRAMANIYAN Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai 600116, Tamil Nadu, India https://orcid.org/0000-0001-6605-5336
ARUL KUTTALINGAM College of Pharmaceutical Sciences, Government Medical College, Thiruvananthapuram 695011, Kerala, India
DAMODHARAN NARAYANASAMY SRM College of Pharmacy, SRM University, Kattankulathur 603203, Tamil Nadu, India

DOI:

https://doi.org/10.22159/ijap.2023v15i3.47265

Keywords:

Tacrolimus, Croscarmellose sodium, Sublingual, Fast dissolving films, Central composite design

Abstract

Objective: The study aimed to develop fast-dissolving films (FDFs) of the immunosuppressant drug tacrolimus monohydrate for sublingual administration, employing central composite design (CCD), to improve its bioavailability.

Methods: Tacrolimus: β-cyclodextrin inclusion complexes prepared earlier were formulated into FDFs. CCD was used for developing optimal film formulation with the desired characteristics. The solvent casting method was used for the preparation of films. For optimization, the independent variables selected were the concentration of hydroxy propyl methyl cellulose E5 (HPMC E5) (X₁) and concentration of croscarmellose sodium (CCS) (X₂) and the responses were disintegration time (Y₁) and percentage drug release at 5 min (Y₂). The suggested optimal films were subjected to further characterization.

Results: All the formulations showed good mechanical properties. The composition of optimized FDF constituted 3.016% w/v of HPMC and 11.731%w/w of CCS and its average disintegration time was 27.28s and showed 83.13% mean drug release at 5 min. Differential Scanning calorimetry (DSC) analysis showed complete dispersion and partial conversion into the amorphous form of the drug, which was also confirmed by X-ray diffraction (XRD) studies. Scanning Electron Microscopy (SEM) revealed the smooth and porous nature of the film.

Conclusion: The developed FDF may be used sublingually for delivering tacrolimus efficiently, avoiding its oral bioavailability problems.

Downloads

Download data is not yet available.

References

Dharmasthala S, Shabaraya AR, Andrade GS, Shriram RG, Hebbar S, Dubey A. Fast dissolving oral film of piroxicam: solubility enhancement by forming an inclusion complex with β-cyclodextrin, formulation and evaluation. J Young Pharm. 2018;11(1):1-6. doi: 10.5530/jyp.2019.11.1.

Londhe V, Shirsat R. Formulation and characterization of fast-dissolving sublingual film of iloperidone using box–behnken design for enhancement of oral bioavailability. AAPS PharmSciTech. 2018;19(3):1392-400. doi: 10.1208/s12249-018-0954-y, PMID 29396734.

Suresh BS, Hemraj MT. Design and statistical optimization of mouth dissolving sublingual film of fixed dose combination of doxylamine succinate and pyridoxine hydrochloride using design of experiment in the treatment of nausea and vomiting in pregnancy. Asian J Pharm Clin Res. 2018;11(12). doi: 10.22159/ajpcr.2018.v11i12.27978.

Panraksa P, Tipduangta P, Jantanasakulwong K, Jantrawut P. Formulation of orally disintegrating films as an amorphous solid solution of a poorly water-soluble drug. Membranes. 2020;10(12):1-17. doi: 10.3390/membranes10120376, PMID 33261025.

Mashru RC, Sutariya VB, Sankalia MG, Parikh PP. Development and evaluation of fast-dissolving film of salbutamol sulphate. Drug Dev Ind Pharm. 2005;31(1):25-34. doi: 10.1081/ddc-43947, PMID 15704855.

PH, Fatima S. Formulation and evaluation of oral fast dissolving films of naproxen sodium. Int J Curr Pharm Sci. 2022;14:48-53. doi: 10.22159/ijcpr.2022v14i2.1953.

Watkins KD, Boettger RF, Hanger KM, Leard LE, Golden JA, Hoopes CW. Use of sublingual tacrolimus in lung transplant recipients. J Heart Lung Transplant. 2012;31(2):127-32. doi: 10.1016/j.healun.2011.10.015. PMID 22177691.

Nasiri Toosi Z, Dashti Khavidaki S, Nasiri Toosi M, Khalili H, Jafarian A, Irajian H. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. Exp Clin Transplant. 2012;10(6):586-91. doi: 10.6002/ect.2012.0032, PMID 22770208.

Solari S, Cancino A, Wolff R, Norero B, Vargas JI, Barrera F. Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. Aliment Pharmacol Ther. 2017;45(9):1225-31. doi: 10.1111/apt.14022. PMID 28261844.

Aziz DE, Abdelbary AA, Elassasy AI. Implementing central composite design for developing transdermal diacerein-loaded niosomes: ex vivo permeation and in vivo deposition. Curr Drug Deliv. 2018;15(9):1330-42. doi: 10.2174/1567201815666180619105419, PMID 29921206.

Mohanan J, Palanichamy S, Kuttalingam A, Narayanasamy D. Development and characterization of tacrolimus tablet formulations for sublingual administration. Int J App Pharm. 2021;13(6):89-97. doi: 10.22159/ijap.2021v13i6.42429.

Jadhav YG, Galgatte UC, Chaudhari PD. Overcoming poor solubility of dimenhydrinate: development, optimization and evaluation of fast dissolving oral film. Adv Pharm Bull. 2018;8(4):721-5. doi: 10.15171/apb.2018.081, PMID 30607345.

Haju SS, Yadav S. Formulation and evaluation of cilnidipine mucoadhesive buccal film by solvent casting technique for the treatment of hypertension. Int J Pharm Pharm Sci. 2021;13(9):34-43. doi: 10.22159/ijpps.2021v13i9.42641.

Allam A, Fetih G. Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate. Drug Des Devel Ther. 2016;10:2421-33. doi: 10.2147/DDDT.S113775. PMID 27536063.

Al-Mogherah AI, Ibrahim MA, Hassan MA. Optimization and evaluation of venlafaxine hydrochloride fast dissolving oral films. Saudi Pharm J. 2020;28(11):1374-82. doi: 10.1016/j.jsps.2020.09.001. PMID 33250644.

Senthilkumar K, Vijaya C. Formulation development of mouth dissolving film of etoricoxib for pain management. Advances in Pharmaceutics. 2015;2015:1-11. doi: 10.1155/2015/702963.

Abouhussein DMN, El-Bary AA, Shalaby SH, El Nabarawi MAE. Chitosan mucoadhesive buccal films: effect of different casting solvents on their physicochemical properties. Int J Pharm Pharm Sci. 2016;8(9):206-13. doi: 10.22159/ijpps.2016.v8i9.12999.

The United States pharmacopoeia. The United States of America Pharmacopoeial Convention; 2013. p. 3-5.

Brniak W, Maslak E, Jachowicz R. Orodispersible films and tablets with prednisolone microparticles. Eur J Pharm Sci. 2015;75:81-90. doi: 10.1016/j.ejps.2015.04.006. PMID 25889975.

Bhargav E, Prakash Reddy CS, Sowmya C, Haranath C, Ahmed Khan KA, Rajesh K. Formulation and optimization of piroxicam orodispersible tablets by central composite design. J Young Pharm. 2017;9(2):187-91. doi: 10.5530/jyp.2017.9.37.

Chaudhary H, Gauri S, Rathee P, Kumar V. Development and optimization of fast dissolving oro-dispersible films of granisetron HCl using box-behnken statistical design. Bull Fac Pharm Cairo Univ. 2013;51(2):193-201. doi: 10.1016/j.bfopcu.2013.05.002.

Rezaee F, Ganji F. Formulation, characterization, and optimization of captopril fast-dissolving oral films. AAPS PharmSciTech. 2018;19(5):2203-12. doi: 10.1208/s12249-018-1027-y, PMID 29728997.

Shen C, Shen B, Xu H, Bai J, Dai L, Lv Q. Formulation and optimization of a novel oral fast dissolving film containing drug nanoparticles by box–behnken design–response surface methodology. Drug Dev Ind Pharm. 2014;40(5):649-56. doi: 10.3109/03639045.2014.884116, PMID 24506458.